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Abstract
Background: During the recent H1N1 influenza pandemic, excess morbidity and mortality was seen in young but not older
adults suggesting that prior infection with influenza strains may have protected older subjects. In contrast, a history of
recent seasonal trivalent vaccine in younger adults was not associated with protection.
Methods and Findings: To study hemagglutinin (HA) antibody responses in influenza immunization and infection, we have
studied the day 7 plasma cell repertoires of subjects immunized with seasonal trivalent inactivated influenza vaccine (TIV)
and compared them to the plasma cell repertoires of subjects experimentally infected (EI) with influenza H3N2 A/Wisconsin/
67/2005. The majority of circulating plasma cells after TIV produced influenza-specific antibodies, while most plasma cells
after EI produced antibodies that did not react with influenza HA. While anti-HA antibodies from TIV subjects were primarily
reactive with single or few HA strains, anti-HA antibodies from EI subjects were isolated that reacted with multiple HA
strains. Plasma cell-derived anti-HA antibodies from TIV subjects showed more evidence of clonal expansion compared with
antibodies from EI subjects. From an H3N2-infected subject, we isolated a 4-member clonal lineage of broadly cross-reactive
antibodies that bound to multiple HA subtypes and neutralized both H1N1 and H3N2 viruses. This broad reactivity was not
detected in post-infection plasma suggesting this broadly reactive clonal lineage was not immunodominant in this subject.
Conclusion: The presence of broadly reactive subdominant antibody responses in some EI subjects suggests that improved
vaccine designs that make broadly reactive antibody responses immunodominant could protect against novel influenza
strains.
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Influenza is a persistent threat to public health with seasonal
influenza causing .200,000 hospitalizations and .35,000 deaths
in the US annually [1,2]. While the most recent pandemic strain
did not appear to be significantly more pathogenic than the
seasonal strain of influenza that it replaced [3], prior pandemics,
such as the 1918 H1N1 influenza pandemic, have been associated
with severe mortality [4].
Immunization of susceptible populations is one of the primary
methods for preventing influenza-associated morbidity and mortal-
ity [5]. In humans, boosting immunizations with trivalent
inactivated influenza vaccine (TIV) are associated with the transient
appearance of influenza-specific plasma cells/plasmablasts (hereaf-
ter termed plasma cells) in peripheral blood [6]. The majority of
these plasma cells produce antibodies that bind HA and are both
strain-specific and neutralizing [6]. Protective humoral responses to
influenza are mediated by antibodies that prevent infection of target
cells, and these antibodies are largely directed against variable
regions of the HA globular head leading to subtype- and strain-
specific antibody responses [7,8]. Broadly neutralizing antibodies
reactive with multiple influenza subtypes have been isolated from
phage-displayed libraries from uninfected subjects [9], those
recovering from H5N1 influenza [10], and those vaccinated against
seasonal influenza [11], but such antibodies are not immunodomi-
nant and generally are not found in plasma [12].
In order to perform a direct comparison between the antibody
repertoires following influenza immunization and infection, we
isolated plasma cells from human peripheral blood at seven days
following TIV or experimental influenza infection (EI) with H3N2
A/Wisconsin/67/2005 by using single cell sorting. PCR-based
amplification of V(D)J gene rearrangements of Ig heavy- and light-
chains present in single plasma cells was used for analysis and gene
recovery for subsequent mAb expression. We found that plasma-
cell-derived mAbs from EI were more polyclonal but anti-HA
mAbs from EI were more cross-reactive compared to mAbs
derived from TIV subjects. The anti-HA response in TIV showed
more evidence of clonal expansion and was more strain-specific
compared to the response in EI. The largest clonal lineage
identified from an EI subject contained anti-HA mAbs that
reacted with most HAs tested and neutralized both H1N1 and
H3N2 influenza A strains.
Results
Similar Frequencies of Circulating Plasma Cells Following
TIV and EI
We studied a group of five subjects immunized with TIV and six
subjects enrolled in a protocol of EI with influenza H3N2 A/
Wisconsin/67/2005 [13] (Table 1). At 21 days after immuniza-
tion, all TIV subjects showed a .4-fold rise in antibody titer for
HA binding for those components in the vaccine (Fig. S1 online)
and a rise in influenza neutralization titer vs. H1N1 A/Solomon
Islands/03/2006 or H3N2 A/Wisconsin/67/2005 (Table 1). At
28 days after experimental infection, 5/6 EI subjects had a .4-
fold rise in antibody titer against the infecting strain H3N2 A/
Wisconsin/67/2005 (Fig. S1 online). For one subject, EI03, no
convalescent sample was available; testing of the day 7 sample
showed a 3.7-fold rise in titer against the infecting strain (Fig. S1
online). Neutralization titers rose for all EI subjects [2-fold to 16-
fold rise; Table 1]. Symptom severity did not correlate with
infecting dose (Table 1).
As described [14] we analyzed PBMC for the presence of
plasma cells (CD3/14/16/235a
2 CD19
+ CD20
2/lo CD27
hi
CD38
hi) seven days after TIV or EI. There was no difference in
plasma cell frequencies between five TIV subjects and six EI
subjects as a percentage of the total B cell population (CD3/14/
16/235a
2 CD19
+) in PBMC [TIV mean 2.75%60.90%; EI mean
2.2660.74%; two-tailed t test, p=0.68] (Fig. 1A; Fig. S2 online).
Higher Frequencies of Influenza-Specific Plasma Cells
After TIV
We isolated single plasma cells from both TIV and EI subjects
for the generation of recombinant (r) mAb [14], recovering 404
mAbs from five TIV subjects and 451 mAbs from six EI subjects
(Figs. 1B, 1C; Fig. S3 online). The characteristics of all recovered
rmAbs are displayed in Tables S3,S4, S5, S6, S7, S8, S9, S10 and
Figures S6, S7 online. All 855 rmAbs were tested in ELISA and
LuminexH-based assays for reactivity with a panel of nine
baculovirus-expressed rHAs and split-virus vaccine preparations
(TIV for 2007–2008 or 2008–2009 seasons; see Methods). Split-
virus vaccines contain immunogenic HA as well as neuraminidase,
nucleoprotein, matrix proteins, and membrane fragments [15].
Almost two-thirds (252/404 rmAbs; 62.4%) of TIV rmAbs reacted
with TIV or rHA while fewer than 10% (37/451 rmAbs: 8.2%) of
rmAbs from EI subjects did (x
2=279.5, p,0.0001) (Fig. 1B).
Thus, while TIV and EI were associated with a similar degree of
plasmacytosis, the circulating plasma cells at 7 days in EI were less
frequently HA-specific.
Increased Clonal Relatedness After TIV
We next analyzed the Ig heavy chain (HC) and light chain (LC)
gene sequences from all 855 mAbs for clonal relatedness and found
that mAbs from TIV subjects were more likely to fit in clonal
lineages than mAbs from EI subjects (Fig. 1C; Table S1, Table S2,
Fig. S4 online). From TIV subjects, 175/404 (43.3%) mAbs could
be arranged into 46 clonal lineages containing 2–19 unique
members (Table S1 online). In contrast, 28/451 (6.2%) mAbs from
EI subjects could be arranged into one of 12 clonal lineages
containing 2–4 unique members (Table S2 online) (Fig. 1C)
(x
2=162.1, p,0.0001). Clonal expansion was detected in most
subjects [4/5 (80%) of TIV subjects; 4/6 (67%) of EI subjects];
TIV14, EI02, and EI07 lacked evidence for clonal expansion.
Of the 46 clonal lineages identified from TIV subjects, 44 (96%)
had at least one rmAb that reacted with influenza antigens; clonal
lineages containing rmAbs reactive with influenza antigens were
found in all four TIV subjects with identified clonal lineages (Table
S1 online). In contrast, of the 12 clonal lineages recovered from EI
subjects, only 2 (17%) contained members reactive with rHAs and
split-virus vaccine preparations (Table S2 online). Both influenza-
reactive lineages were from one subject (EI13) and all rmAbs from
these two lineages reacted with rHA. Ninety-one percent (159/
175) of rmAbs in TIV clonal lineages were reactive with influenza
antigens (Table S1 online) while only 21% (6/28) of clonal
members from EI subjects were reactive with influenza antigens
(Table S2 online) (x
2=76.5, p,0.0001). When viewed as a
proportion of all rHA-specific mAbs, antibodies from TIV were
more likely to be in a clonal lineage (159/252; 63.1%) compared
to mAbs from EI (6/37; 16.2%) (Fig. 2A; Fig. S4 online) (x
2=28.9,
p,0.0001). Thus, while EI and TIV were associated with a similar
degree of plasmacytosis, TIV was associated with more clonal
expansion of plasma cells making anti-HA antibodies.
Cross-reactive rmAbs Recovered from TIV and EI
Using a panel of 9 rHAs representing diverse temporal (1994–
2009) and antigenic (influenza A H1, H3, H5 and influenza B)
strains, we tested all 855 rmAbs for their ability to bind rHAs in
Influenza Ab Cross-Reactivity/Clonal Expansion
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binding to split-virus TIV preparations from the 2007–2008 and
2008–2009 seasons. The majority of influenza-specific mAbs
isolated from TIV subjects were strain-specific (159/252; 63%)
while rmAbs reactive with single influenza HA strains were less
common in EI subjects (16/37; 43%) (x
2=7.74, p=0.0054)
(Fig. 2B). In contrast, rmAbs cross-reactive with 3 or more
influenza HA strains were much less common in TIV compared to
EI subjects [14/252 (5.6%) vs. 13/37 (35%), respectively;
x
2=33.3, p,0.0001] (Fig. 2B, Table S11 online). We found
cross-reactive rmAbs associated with clonal expansion in both
groups; 6/14 (43%) cross-reactive rmAbs from TIV were members
of four clonal lineages while 4/13 (31%) of cross-reactive rmAbs
from EI were in a clonal lineage (Tables S1, S2, S11 online).
TIV rmAb Reactivity Is Similar to Plasma Antibody
Specificities
The antibody response in TIV subjects was largely restricted to
the subtypes present in the administered vaccine and for most
subjects was strain-specific (Text S1, Figs. S1, S8 online). The
strain specificity of the response was most striking in the rmAb-
binding pattern against rHAs (Text S1, Figs. S1, S8 online). In EI
subjects plasma antibody rose more modestly (Fig. S1 online) and
recovered rmAbs were less strain specific (Fig. S8 online). The
most broadly cross-reactive anti-HA rmAbs were recovered from
subject EI13 (Fig. 3; Fig. S8, Table S11 online); comparison of
plasma antibody at time zero and 28 days after infection
demonstrated a 13-fold increase in rHA H3 A/Wisconsin/67/
2005 binding (Fig. S1 online) but only a 2-fold rise in virus
neutralization titer to that strain (Table 1). Thus, the broad
neutralizing rmAbs isolated from EI13 (Fig. 3) did not contribute
significantly to plasma antibody 28 days following EI.
Higher Frequency of Original Antigenic Sin (OAS)
Antibodies in EI
OAS antibodies are defined as rmAbs that react with rHAs to
whichthesubjectwasexposedbeforethecurrentvaccineorinfection
[12,16,17,18,19]. In this study, OAS rmAbs reacted with rHA
strains not contained in the administered vaccine for TIV subjects or
with the infecting H3N2 A/Wisconsin/67/2005 strain for EI
subjects. From TIV subjects, 5/252 (2%) rmAbs were consistent
with OAS (Fig. 2C, Table 2). In contrast, from EI subjects, 7/37
(19%) influenza-specific rmAbs had rHA binding consistent with
OAS (Fig. 2C, Table 2); those rmAbs reacted with influenza A H3
rHAs, influenza B rHA, and trivalent vaccine from 2008–2009
(Table 2). Thus, OAS rmAbs from EI subjects comprised a greater
proportionofinfluenza-reactivermAbscomparedtothosefromTIV
subjects (x
2=19.2,p,0.0001) (Fig. 2C).
Cross-reactive rmAbs (Table S11 online) did not have
characteristics of OAS; in fact, no OAS rmAb reacted with more
than two rHAs (Table 2). The most common specificity of OAS
rmAbs was to rHA H3 A/Johannesburg/33/1994 (TIV 3/5, EI
5/10), a strain isolated more than a decade before the current
study was performed. Comparison of the infecting strain with
other H3 rHAs tested showed that the Johannesburg strain was
least similar (88% amino acid identity vs. 96–98% for other tested
strains; Fig. S12 online) suggesting that rHA sequence homology
was not responsible for eliciting these antibodies. OAS mAbs were
more frequently recovered from the same EI subjects from whom
the most broadly cross-reactive mAbs derived, suggesting that
these populations were stimulated in parallel during EI. Thus, TIV
is characterized by few OAS mAbs, clonal expansion of anti-HA
responses, and seroconversion to the vaccine; while EI is
characterized by more OAS mAbs, less clonal expansion of anti-
HA responses, and weaker seroconversion to the infecting strain.
Table 1. Subject Characteristics.
Subject ID Age Gender Immunogen Peak Sx Score
{ Change in Neutralization Titer from d0 to d21
vs. H1 SI
" vs. H3 Wisc
TIV01 18 Male TIV 2007* N/A 1:20 to .1:1280 1:160 to 1:1280
TIV04 42 Male TIV 2007 N/A 0 to 1:240 0 to 1:320
TIV14 37 Male TIV 2008* N/A 1:80 to 1:80 (no D) 0 to 1:40
TIV21 26 Male TIV 2008 N/A 0 to 1:240 0 to 1:160
TIV24 20 Female TIV 2008 N/A 1:80 to .1:1280 1:10 to 1:640
mean 28.6
Subject ID Age Gender Infecting Strain Peak Sx Score
{ Change in Neutralization Titer from d0 to d28
vs. H1 SI
" vs. H3 Wisc
EI02 28 Male H3 Wisc 10
6 TCID50
{ 0 1:40 to 1:40 (no D) 1:10 to 1:40
EI03 24 Male H3 Wisc 10
6 TCID50 0 not done 0 to 1:10
1
EI05 25 Female H3 Wisc 10
5 TCID50 12 1:10 to 1:10 (no D) 1:20 to 1:320
EI07 35 Male H3 Wisc 10
5 TCID50 12 0 to 0 (no D) 0 to 1:80
EI12 27 Male H3 Wisc 10
4 TCID50 4 1:40 to 1:40 (no D) 1:10 to 1:80
EI13 29 Female H3 Wisc 10
3 TCID50 2 not done 1:40 to 1:80
mean 28.0
*TIV 2007=inactivated trivalent influenza vaccine for 2007–2008 season; TIV 2008=inactivated trivalent influenza vaccine for 2008–2009 season.
{Modified Jackson score [48]. N/A=not applicable.
"H1 SI=H1N1 A/Solomon Islands/03/2006; H3N2 Wisc=H3N2 A/Wisconsin/67/2005.
{Number shown is relative inoculum.
1Sample is from d7; d28 sample not available.
doi:10.1371/journal.pone.0025797.t001
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rmAbs in a Single Clonal Lineage From an Influenza
Vaccinated Subject
Clonal lineages from TIV subjects were commonly recovered and
largely influenza strain-specific (Table S1 online). Analysis of lineage
641 recovered from TIV01 showed remarkable divergence in rHA
reactivity within the clonal lineage (Fig. 4). This lineage is composed
of IgG1 and IgA1 members (10/18 and 8/18, respectively), and
rmAbs in the upper portion of the lineage reacted primarilywith rHA
H1 A/Solomon Islands/03/2006 (15/18, 83%). For example, rmAb
1270 displayed high affinity for H1 A/Solomon Islands/03/2006
and much lower affinity for H1 A/Brisbane/59/2007 (Fig. 4). These
data were consistent with the neutralization pattern of rmAb 1270
that inhibited H1N1 A/Solomon Islands/03/2006 at 0.02 mg/mL
but did not inhibit H3N2 A/Wisconsin/67/2005.
One of the IgA1 branches of lineage 641 was composed of six
members (rmAbs 692, 1190, 1205, 1218, 1232, and 2249), two of
which (1205, 1218) did not bind to any rHA tested (Fig. 4). To
study affinity maturation in this lineage branch, we produced
inferred intermediate antibodies #3 and #5 (Fig. 4) and these
bound with high affinity to H1 A/Solomon Islands/03/2006 but
did not bind to other rHAs. The more distantly related branch
point intermediate #15 also bound only to H1 A/Solomon
Islands/03/2006 but with lower affinity (Fig. 4). These data are
consistent with affinity maturation occurring within this branch of
clone 641.
Remarkably, IgG1 clonal lineage members in the bottom
portion of the 641 tree displayed both an increased affinity for
rHA H1 A/Solomon Islands/03/2006 and to other rHAs (Fig. 4).
In particular, intermediate #9 bound with high affinity to H1 A/
Solomon Islands/03/2006, with moderate affinity to both H1 A/
Brisbane/59/2007 and pandemic H1 A/California/04/2009, and
with weak affinity to H3 A/Wisconsin/67/2005 (Fig. 4). However,
this rHA binding breadth was lost in some more distant members
of the lineage (e.g., rmAb 2258; Fig. 4). Intermediate #11 did not
bind rHA H3 A/Wisconsin/67/2005 and showed weak affinity for
novel H1 A/California/04/2009; the two rmAbs derived from this
intermediate (rmAbs 1261 and 676) retained similar breadth and
affinity of rHA binding as intermediate #11 (Fig. 4). Subject
TIV01 from whom this lineage was derived showed a greater rise
in plasma H1N1 A/Solomon Islands/03/2006 neutralization
(Table 1) and binding titer (Fig. S1 online) compared to the rise
against H3N2 A/Wisconsin/67/2005; and the rmAbs in lineage
641 recapitulate this finding.
Overall, nine lineages from TIV subjects showed evidence of
class switching with IgG1 to IgA1 class switching being most
common (7/9 lineages; Table S1 online). Additional clonal
lineages from subjects TIV01 and TIV21 are presented in the
supporting materials online (Text S1, Figs. S10 and S11 online).
Broadly Reactive Clonal Lineage 2569 from H3N2
Infected Subject EI13
As noted, clonal lineages from EI subjects were detected less
frequently than from TIV subjects, and only two clonal lineages
had rmAbs reactive with influenza antigens (Table S2 online). The
largest clonal lineage from subject EI13 consisted of four highly
cross-reactive mAbs (Fig. 3, Table 3; Table S11 online). This
lineage had one IgA1 and three IgM members; each member of
this lineage had a VDJ mutation frequency higher than the
average for influenza-specific mAbs from EI (range 8.7–14.4%; EI
overall mean 8.6%; Fig. S5 online). Members of this lineage bound
rHAs of H1N1 A/Solomon Islands/03/2006 and H3N2 A/
Wisconsin/67/2005 in surface plasmon resonance (Fig. S9B, S9C
online) and blocked hemagglutination of these two strains
(Table 3). These rmAbs also neutralized five temporally distinct
H3N2 viruses as well as H1N1 A/Solomon Islands/03/2006
(Table 3). High affinity binding to H3 rHA proteins, lower affinity
for H5 rHAs and even lower affinity for rHA of the pandemic
H1N1 A/California/04/2009 strain paralleled the observed
pattern of neutralizing activity (Table 3, Fig. 3). The highest
affinity binding in clonal lineage 2569 was observed to a
temporally remote strain, H3 A/Johannesburg/33/1994 (Fig. 3)
that has lower sequence homology to the infecting strain than
other tested rHAs (Fig. S12 online). As noted above, broadly HA-
reactive antibodies did not boost (Fig. S1 online) nor did
neutralizing antibodies persist as a high-titered response in this
subject (Table 1). These data suggest that in this subject, H3N2 A/
Wisconsin/67/2005 stimulated a subdominant clone of B cells
capable of making broadly neutralizing antibodies but that those
Figure 1. Characterization of peripheral blood plasmacytosis 7
days after TIV or EI. A. Peripheral blood B cells (CD3/14/16/235a
2
CD19
+) stained for plasma cell markers (CD3/14/16/235a
2 CD19
+
CD20
2/lo CD27
hi CD38
hi); points shown are percentage of B cells that
were plasma cells. TIV mean 2.75%60.90%; EI mean 2.2660.74%; two-
tailed t test, p=0.68. B. Human rmAbs derived from sorted plasma cells
tested for reactivity. From TIV subjects, 252/404 rmAbs (62.4%) reacted
with $1 influenza antigen (blue wedge), 152/404 (37.6%) did not react
with any tested rHA or split-virus antigen (gray wedge). From EI
subjects, 37/451 rmAbs (8.2%) reacted with $1 influenza antigen
(tested vs. TIV, x
2=279.5, p,0.0001), 414/451 (91.8%) did not react with
any tested rHA or split-virus antigen. C. Human rmAbs membership in
clonal lineages. From TIV subjects, 175/404 (43.3%) rmAbs were
members of 46 clonal lineages (red wedge); from EI subjects, 28/451
(6.2%) rmAbs were members of 12 clonal lineages (x
2=162.1,
p,0.0001).
doi:10.1371/journal.pone.0025797.g001
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influenza-specific rmAbs were members of 44 clonal lineages (purple wedge); from EI subjects, 6/37 (16.2%) were members of 2 clonal lineages
(x
2=28.9, p,0.0001). B, Multiple reactivity to influenza antigens. From TIV subjects, 159/252 (63%) of rmAbs were strain-specific (blue wedge);
multiply reactive rmAbs were less common [two antigens 79/252 (31.4%) (yellow wedge); three antigens 11/252 (4.4%) (orange wedge); four antigens
2/252 (0.8%) (red wedge); five antigens 1/252 (0.4%) (black wedge)]. From EI subjects, 16/37 (43.2%) were strain-specific (x
2=7.74, p=0.0054);
multiply reactive mAbs were more common [two antigens 8/37 (21.6%); three antigens 8/37 (21.6%); four antigens 3/37 (8.1%); five antigens 1/37
(2.7%); six antigens 1/37 (2.7%) (white wedge)]. C. Original antigenic sin rmAbs. From TIV subjects, 5/252 (2%) of influenza-specific rmAbs did not
react with strains contained in the administered vaccine but only with previously circulating influenza antigens (striped wedge). From EI subjects,7 /
37 (19%) of influenza-specific rmAbs did not react with the infecting strain but only with previously circulating antigens (x
2=19.2, p,0.0001).
doi:10.1371/journal.pone.0025797.g002
Figure 3. Clonal lineage 2569 from EI13. Three of 4 members (75%) derived from IgM-expressing plasma cells, 1/4 (25%) derived from an IgA1
plasma cell. The highest affinity binding for all members was to H3 Jobg; high affinity binding to other H3 rHAs and H1 Bris was also observed. Three
members were tested for HAI and neutralization and displayed similar breadth (Table 3). H1 SI=H1N1 A/Solomon Islands/03/2006; H1 Bris=H1N1 A/
Brisbane/59/2007; H1 Cal=H1N1 A/California/04/2009; H3 Wisc=H3N2 A/Wisconsin/67/2005; H3 Bris=H3N2 A/Brisbane/10/2007; H3 Jobg=H3N2 A/
Johannesburg/33/1994; H5 Indo=H5N1 A/Indonesia/05/2005; H5 Viet=H5N1 A/Vietnam/1203/2004.
doi:10.1371/journal.pone.0025797.g003
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pool at day 28 after infection (Table 1; Fig. S1 online).
Discussion
In this study, we compared the plasma cell repertoires present at
7 days following TIV and EI. Previous studies have shown that
influenza-specific plasma cells appear transiently in the blood with
a peak at 7 days after immunization following which they rapidly
decline [6]. Studies of infection, however, have been limited to
natural infection where timing must be estimated based on
exposure and symptoms [20], or where the infection occurred
months to years before antibodies were isolated [10,21,22]. This
study of vaccination and experimental infection allowed us to
compare the two stimuli at exactly the same point after challenge.
We found a similar degree of plasmacytosis in the two conditions
but found that the frequency of HA-specific plasma cells and the
degree of clonality of those cells was lower in the EI group. These
findings differ from studies of natural infection where both a
higher frequency and clonality of influenza-specific antibodies
were found [20]. Trafficking of B cells after infection may have a
different kinetic pattern than that following vaccination. This EI
study stopped collecting cell samples at 7 days post-infection and
so future studies of later time points will be required to determine
if the polyclonality of the plasma cell response we observed is
specific for the period early after infection, specific for H3N2 A/
Wisconsin/67/2005 infection, or if infection with novel pandemic
strains consistently stimulates B cell clonal expansion.
For each subject there was an increase in rHA binding and
neutralization titers 3–4 weeks after antigen stimulation. The
magnitude of rise was greater in the TIV cohort although all EI
subjects showed a rise in titer against the infecting strain that was
similar to that observed in outbreak situations [23]. The presence
of asymptomatic but productive infection is common and has been
observed for seasonal influenza [24], pandemic H1N1 [23], and
human infection with avian H5N1 [25]. Thus, we found it
interesting that similar frequencies of rHA-specific antibodies were
recovered from subjects with the highest and lowest symptom
scores (Fig. S3 online), and that the most broadly cross-reactive
rmAbs were recovered from a subject with mild symptoms and a
modest rise in binding and neutralization titer. Whether this
response contributed to the mild symptoms experienced by this
subject is unknown and future studies will have to address the
potential therapeutic role for this group of rmAbs.
The plasma-cell-derived mAbs from TIV subjects were more
frequently rHA-specific and showed evidence of clonal expansion
while mAbs derived from EI subjects were less frequently rHA-
specific and had less evidence of clonal expansion. In all subjects,
anti-HA responses were primarily strain-specific, but mAbs
derived from EI subjects were more frequently cross-reactive for
multiple influenza strains or consistent with OAS compared with
mAbs derived from TIV subjects. In the EI cohort, responses to
influenza proteins induced by infection that were not detected in
our assays may have been present. Although split-virus vaccines
like that we used for screening contains antigens other than HA
[15], the presence of antibodies reactive with antigens not tested
by our assays cannot be excluded. Isolation of rmAbs from both EI
and TIV subjects reactive only with split-virus vaccine prepara-
tions (Fig. S8 online) suggests that some recovered rmAbs were
reactive with antigens other than HA.
Vaccination is the primary means to prevent seasonal [5] and
pandemic [26] influenza infection, however, antibody responses to
TIV are generally not broadly-neutralizing but rather strain-
specific and directed at highly variable domains on HA [7,8]. Such
responses are not absolute—one rmAb isolated from TIV01 was
recently shown to have cross-reactivity related to its ability to
recognize the sialic acid receptor-binding pocket of HA [27].
Vaccines that bypass regions of diversity by targeting other
influenza proteins [e.g., the virus-associated proton-channel M2
[28]] have not been successful in clinical trials [29]. Targeting
conserved regions on HA could provide a route to a ‘‘universal’’
influenza vaccine [8,30,31], but seasonal vaccines have not
consistently induced these specificities of antibodies as shown in
our study. Influenza vaccination strategies using novel adjuvants
may induce a greater antibody breadth against HA [32] and it will
be of interest to compare mAbs derived from newer vaccines with
those currently in use.
Table 2. Characteristics of OAS rmAbs.
Subject
ID rmAb ID Lineage* Isotype HC Usage
HC CDR3
Length
HC
Mutation LC Usage
LC CDR3
Length Reactivity
{
TIV01 1318 1329 A1 VH 4-30 JH 6 18 2.7% k Vk 3-20 Jk 2 10 B Fla, TIV 2008
{
TIV24 2516 N/A G1 VH 3-15 JH 6 16 10.2% l Vl 3-21 Jl 1 11 H3 Wisc, H3 Jobg
TIV24 2523 N/A G1 VH 3-15 JH 6 16 8.4% k Vk 1-33 Jk 5 9 H3 Jobg
TIV24 2549 N/A G1 VH 3-13 JH 6 21 10.5% k Vk 1-39 Jk 49 H 1 S I
TIV24 2575 N/A G1 VH 3-15 JH 6 16 4.7% k Vk 1-39 Jk 4 9 H3 Jobg
EI03 1938 N/A G1 VH 4-31 JH 6 19 10.3% k Vk 1-39 Jk 5 9 H3 Jobg
EI03 1974 N/A G1 VH 3-74 JH 4 17 10.3% k Vk 3-11 Jk 2 9 H3 Jobg
EI03 1975 N/A A1 VH 2-70 JH 1 17 5.5% l Vl 1-40 Jl 3 11 H3 Jobg
EI03 1997 N/A G1 VH 1-69 JH 5 14 10.8% k Vk 1-13 Jk 4 9 H3 Jobg, H3 Bris
EI13 2318 N/A A2 VH 1-2 JH 4 16 10.1% l Vl 1-51 Jl 2 11 B Fla
EI13 2423 N/A G1 VH 3-9 JH 4 18 4.8% k Vk 1-39 Jk 4 9 H3 Jobg, H3 Bris
EI13 2431 N/A G1 VH 3-13 JH 4 14 9.4% l Vl 1-44 Jl 3 11 H3 Bris
*Lineage ID from Table S1 (available online). N/A=not applicable.
{B Fla=HA B/Florida/04/2006; H3 Wisc=H3 A/Wisconsin/67/2005; H3 Jobg=H3 A/Johannesburg/33/1994; H1 SI=H1 A/Solomon Islands/03/2006; H3 Bris=H3 A/
Brisbane/10/2007; TIV 2008=trivalent influenza vaccine 2008–2009 season.
{Reactivity to TIV08 could represent cross-reactivity to the B/Florida/04/2006 component.
doi:10.1371/journal.pone.0025797.t002
Influenza Ab Cross-Reactivity/Clonal Expansion
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e25797By producing inferred intermediate antibodies of one clonal
lineage, we found evidence of induction and modulation of
antibody breadth stimulated by TIV (clonal lineage 641; Fig. 4).
This evidence of affinity maturation in humans is similar to
findings in mice [33,34] that were used as evidence of V(D)J
mutation as the source of affinity maturation [35]. Clonal lineage
641 was remarkable in that some inferred intermediate rmAbs
showed a greater breadth of rHA binding than the recovered
rmAbs, suggesting that continued affinity maturation might have
eliminated rHA cross-reactivity. Our novel observation of a
branch displaying cross-reactivity in an otherwise strain-specific
clonal lineage implies that making such cross-reactive branches
immunodominant through novel vaccine strategies could lead to
improved cross-strain protection.
In contrast to the findings in TIV subjects, we found that EI
subjects showed less evidence of clonal expansion seven days after
infection despite having plasma cell antibodies with a higher
frequency of VDJ mutations. Our observation of polyclonal
activation after EI is similar to that seen in animals after c-
herpesvirus infection [36]. This suggests that in our EI subjects
either B cell clonal expansion was not required for circulation of B
cells at seven days after infection expressing affinity matured cross-
reactive antibodies, and/or that the circulation dynamics of HA-
specific plasma cells seven days after infection was different than
that observed after vaccination.
The human mAb response to influenza infection has been
studied in survivors of H5N1 avian influenza [10,22] and in
isolation of mAbs from survivors of the 1918 H1N1 pandemic
[21]; in these studies some mAbs were cross-reactive with related
strains [21] and some mAbs also displayed cross-protection for
novel influenza strains [22,37]. While broadly cross-reactive
neutralizing antibodies against influenza can be induced with
TIV, these responses are not sufficiently immunodominant to
result in high-titer neutralizing antibodies that provide protection
against infection with highly divergent strains. Our data
demonstrate this phenomenon directly, in that cross-reactive
rmAbs and inferred intermediates were found in the plasma cell
repertoires of both TIV and EI subjects while such cross-reactive
antibodies were less prominent or not detected in day 21 or day 28
plasma samples.
Work in mice suggested that some anti-influenza responses can
be associated with restriction of Ig gene usage [38], and recent
work has suggested that human antibodies with broad cross-
reactivity may preferentially derive from restricted Ig gene pools
[10,11,36]. Phage-displayed antibody libraries screened for
binding to H5 HA were enriched for VH1-69 usage [11] and
Figure 4. Clonal lineage 641 from TIV01. During screening, 15/18 rmAbs (83%) bound one influenza antigen (blue dots), 1/18 (6%) bound two
antigens (yellow dot), 2/18 (11%) bound no antigen tested (crossed dots). Antibody 1270 bound rHA H1 SI with high affinity and H1 Bris with weak
affinity. Two branches of the tree derived from IgA1-expressing plasma cells. Inferred intermediates (int) of one of these branches were consistent
with affinity maturation (arrows pointing to circles on the tree indicate the position produced int rmAbs); int #15 bound with lower affinity to H1 SI
than later int #3 or int #5. Branches of the tree near the bottom showed breadth. Int #10 bound only H1 SI; int #9 had higher affinity for H1 SI,
bound H1 Bris and H1 Cal with moderate affinity, and weakly bound H3 Wisc. Int #11 bound H1 Cal more weakly and recovered rmAbs 676 and 1261
bound with a similar pattern. Recovered rmAb 2258 had the highest H1 SI affinity in this part of the lineage but lost cross-reactivity, retaining only
weak reactivity to H1 Cal. Embedded tables show affinity measurements in nM for each rmAb; NB=no binding observed. H1 SI=H1N1 A/Solomon
Islands/03/2006; H1 Bris=H1N1 A/Brisbane/59/2007; H1 Cal=H1N1 A/California/04/2009; H3 Wisc=H3N2 A/Wisconsin/67/2005; H3 Bris=H3N2 A/
Brisbane/10/2007; H3 Jobg=H3N2 A/Johannesburg/33/1994.
doi:10.1371/journal.pone.0025797.g004
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have been produced from IgM
+ memory B cells [39]. Corti et al.
recently reported a series of TIV-induced cross-reactive antibodies
using primarily VH1-69 demonstrating that cells expressing those
antibodies can be isolated following seasonal vaccination [12]; a
strict requirement for VH1-69 was not shown as there were
additional antibodies using VH3-23, VH3-30, VH3-53 and VH4-
39. It was interesting that none of our clonal lineages used VH1-69
and only three cross-reactive antibodies in this study used that VH
gene. This could be due to a lack of VH1-69 gene usage in our
subject population as the frequency of VH1-69 expressing B cells is
related to copy number variation [40], and whether this is the case
for our current subject groups is not known. In our study, other Ig
genes were found to make cross-reactive antibodies including
VH3-23, VH3-74, and VH1-46. One group of these antibodies,
clonal lineage 2569, was remarkable both in the degree of
mutation and that its members were IgM and IgA1. These
findings are consistent with the recall of an IgM
+ memory B cell
lineage expressing a broadly cross-reactive antibody response that
appeared transiently following infection but that did not
predominate in plasma four weeks after infection. A similar
phenomenon has been observed following TIV with isolation of
broadly reactive subdominant antibodies that did not predominate
in convalescent plasma [12]. In our EI subject, stimulation of a
subdominant response may have contributed to the mild
symptoms experienced by this subject and could reflect one
mechanism by which antibody responses contribute to control of a
virus infection without resulting in long-lasting antibody titers.
These findings are also consistent with Pape et al. who reported
that class-switched memory B cells have different circulation
kinetics compared to IgM memory B cells, with the latter
persisting for longer periods but also being subject to suppression
in the presence of cross-reactive plasma antibodies [41].
Finally, OAS antibodies were more frequent among mAbs
derived from EI subjects compared with TIV subjects. Prior
studies have shown that OAS occurs following both influenza
vaccination [18] and infection [16,19], although work by
Wrammert et al. suggested that OAS in humans following
influenza vaccination was uncommon; our study of TIV subjects
is consistent with Wrammert et al. [6]. That the majority of OAS
mAbs were reactive with HA from the H3 A/Johannesburg/33/
1994 strain is consistent with both prior exposure to that strain and
recall by immunization with H3N2-containing vaccine or by
infection with H3N2 influenza virus.
Regardless, the presence of both OAS and cross-reactivity in
mAbs from EI subjects suggests that both kinds of antibodies were
stimulated in parallel during infection. Whether these two
processes can be decoupled to only stimulate broadly cross-
reactive antibodies by a vaccine remains unknown. Corti et al.
showed that the H5 anti-HA antibody response following TIV was
detectable but generally weak, both for serum antibodies and
memory B cell frequency [12]. Recent reports have described
vaccine designs that may stimulate more broadly reactive anti-HA
antibodies. Khurana et al. showed increased anti-HA antibody
breadth using an adjuvanted vaccine [32]. Wei et al. [31] and
Wang et al. [42] have demonstrated induction of broad of plasma
antibody responses by sequential immunization with heterologous
HAs, perhaps replicating the cross-protective response that can
occur after multiple seasonal influenza infections in ferrets [43].
The fact that both seasonal influenza vaccination and infection
involve exposure to heterologous HAs on an annual basis, and that
these exposures do not lead to high levels of influenza resistance in
the general population, suggests that sequential exposure to
heterologous HAs by itself is insufficient. Targeting of the
conserved HA stalk to induce antibodies in mice reactive across
influenza subtypes has recently been demonstrated through the use
of synthetic peptides [44] and rHA subunits [45]. It remains to be
seen whether such vaccine strategies will work in humans.
In summary, we have shown that while the anti-HA response in
vaccination and H3N2 A/Wisconsin/67/2005 infection differs in
the degree of clonal expansion present at seven days, broadly
reactive antibodies are induced in both settings. One strategy for
vaccine design to expand B cell clonal lineages of broadly cross-
reactive antibodies may be to create novel HA molecules with
enhanced binding to germline B cell receptors of HA-responsive
naı ¨ve B cells [46,47]. Thus, the study of clonal lineages of
antibodies with HA binding and breadth of influenza neutraliza-
tion in both vaccination and infection could provide guidance for
design of influenza vaccines capable of inducing immunodominant
broadly cross-reactive antibody responses.
Methods
Ethics Statement
All subject recruitment was performed using written informed
consent. For studies performed at Duke University, the Duke
University Health System Institutional Review Board for Clinical
Investigations approved the protocols. For studies performed at
Retroscreen Virology, LTD (Brentwood, UK), the protocol was
approved by the East London and City Research Ethics
Committee 1 (London, UK), an independent institutional review
board (WIRB: Western Institutional Review Board; Olympia,
WA), the Duke University Health System Institutional Review
Board for Clinical Investigations (Durham, NC), and the SSC-SD
IRB (US Department of Defense; Washington, DC). Subjects
recruited at Retroscreen Viorology, LTD also consented to
unspecified future use of their specimens; these specimens were
kept at Duke University in the Clinico-Molecular Predictors of
Presymptomatic Infectious Disease – Biorepository. The research
Table 3. Anti-influenza activity of rmAbs from EI13 Clonal
Lineage 2569.
rmAb ID 2210 2217 2221
HAI (mg/mL)
H1 SI* 0.02 0.04 0.02
H3 Wisc 0.02 0.02 0.02
Neutralization (mg/mL)
{
H1 SI 1.4 4.9 6.2
H1 Bris Neg
1 Neg Neg
H1 Cal Neg Neg Neg
H3 Wisc 0.18 0.61 0.39
H3 Urgy 0.09 0.07 0.1
H3 Vict 0.09 0.19 0.19
H3 NY 0.19 0.15 –
H3 Cal 0.09 0.08 –
*H1 SI=H1N1 A/Solomon Islands/03/2006; H1 Bris=H1N1 A/Brisbane/59/2007;
H1 Cal=H1N1 A/California/04/2009; H3 Wisc=H3N2 A/Wisconsin/67/2005; H3
Urgy=H3N2 A/Uruguay/716/2007; H3 Vict=H3N2 A/Victoria/210/2009; H3
NY=H3N2 A/New York/55/2004; H3 Cal=H3N2 A/California/7/2004.
{Neutralization testing of H5N1 A/Indonesia/05/2005 and H5N1 A/Vietnam/
1203/2004 was negative.
1–=Not assayed/data not available. Neg=neutralization not detected above
assay threshold.
doi:10.1371/journal.pone.0025797.t003
Influenza Ab Cross-Reactivity/Clonal Expansion
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e25797performed was approved by the Duke University Health System
Institutional Review Board for Clinical Investigations either as a
part of the original study or as an exempt study via the
biorepository.
Subjects
Subjects in the TIV group were recruited at Duke University
and were given trivalent inactivated seasonal influenza vaccine
(Sanofi Pasteur, Swiftwater PA): 2007–2008 FluzoneH vaccine
containing A/Solomon Islands/3/2006 (H1N1), A/Wisconsin/
67/2005 (H3N2), and B/Malaysia/2506/2004 was given to
TIV01 and TIV04; 2008–2009 FluzoneH vaccine containing A/
Brisbane/59/2007 (H1N1), A/Uruguay/716/2007 (H3N2) (clas-
sified as a A/Brisbane/10/2007-like strain), and B/Florida/04/
2006 was given to TIV14, TIV21, and TIV24. Blood was drawn
from immunized subjects on day 0 before vaccination and on days
7 and 21 after challenge.
The EI protocol was performed at Retroscreen Virology, LTD
(Brentwood, UK) as previously described [13]. Subjects were
prescreened and provided informed consent before being given an
intranasal challenge. The influenza challenge stock was A/
Wisconsin/67/2005 (H3N2) manufactured from a human isolate
passaged three times in Primary Chick cells, then twice in eggs,
before two final passages in GMP Vero cells. The latter stage of
passaging in GMP Vero cells was accomplished under GMP
conditions at Baxter BioScience (Vienna, Austria). The final
product underwent quality testing for identity, appearance,
sterility, infectivity and adventitious contaminants, and was
assessed according to pre-determined specifications. On the day
of inoculation, volunteers received 10
6.41 (subjects EI02, EI03),
10
5.25 (subjects EI05, EI07), 10
4.41 (subject EI12), and 10
3.08
(subject EI13) TCID50 of the challenge stock. In this protocol,
blood was drawn before challenge, then daily on days 0–7, and on
day 28 after challenge. Cells were only collected on samples
through day 7. Symptoms were recorded twice daily using a
modified Jackson scoring system [48]. Infection was confirmed in
all subjects by the presence of viral shedding in nasal washings,
seroconversion in day 28 serum samples, or both.
Single-Cell Sorting
PBMC were isolated from blood on the day of draw and
cryopreserved using standard techniques until thawed for sorting.
Cryopreservation of PBMC was necessary as one protocol was
carried out in the UK; in order to harmonize the two protocols all
samples were studied after cryopreservation. Single-cell sorting
was performed as previously described [14] using a panel of
antibodies reactive with the following cell surface molecules:
CD138 (FITC), surface IgD (PE), CD3 (PE-Cy5), CD16 (PE-Cy5),
CD235a (PE-Cy5), CD20 (PE-Cy7), CD19 (APC-Cy7), CD27
(PacificBlueH) (BD Biosciences, San Jose, CA); CD38 (APC-Cy5.5)
(eBioscience, San Diego, CA); CD14 (PE-Cy5), CD38 (APC-
Cy5.5) (Invitrogen, Carlsbad, CA); CD38 (APC-AlexaFluorH 647)
(Beckman Coulter, Brea, CA). Plasma cells/plasmablasts were
sorted using a BD FACSAria
TM or a BD FACSAria
TM II (BD
Biosciences, San Jose, CA) by gating on CD3
2 CD14
2 CD16
2
CD235a
2 CD19
+ CD20
2/lo CD27
hi CD38
hi cells. Flow cytom-
etry data was analyzed using FlowJo (Treestar, Ashland, OR). The
fraction of plasma cells isolated from peripheral blood is lower
than the level reported by Wrammert et al. [mean 6.4%] [6]; this
is likely due to the use of cryopreserved PBMC in the present
study.
Single cells were directly sorted into 96-well plates containing
20 mL per well of RT reaction buffer [5 mLo f5 6 first strand
cDNA buffer, 0.5 mL RNaseOUT
TM (Invitrogen, Carlsbad, CA),
1.25 mL dithiothreitol, 0.0625 mL IGEPALH CA-630 (Sigma, St.
Louis, MO), 13.25 mLo fd H 2O (Invitrogen, Carlsbad, CA)]; plates
were stored at 280uC until use and again stored at 280uC until
PCR was performed.
PCR Isolation of Ig VH,V k and Vl Genes
Single cell PCR was achieved as described [6,14,49]. Briefly,
reverse transcription (RT) was performed using 50 units per
reaction Superscript III reverse transcriptase (Invitrogen, Carls-
bad, CA) and 0.5 mM human constant region primers (IgG, IgA1,
IgA2, IgM, IgD, Igk,I g l)a t3 7 uC for 1 h. Separate reactions were
used to amplify individual families of VH,V k, and Vl genes from
the cDNA template; this was performed using two rounds of PCR
[first round: 5 mL of RT reaction product, 5 units HotStar Taq
Plus (QIAGEN, Valencia, CA), 0.2 mM dNTPs, 0.5 mM nested
constant region primers (IgH consisting of IgM, IgD, IgG, IgA1,
IgA2; Igk;o rI g l) and matched variable region primers; second
round: 2.5 mL of first round reaction product, 5 units HotStar Taq
Plus (QIAGEN, Valencia, CA), 0.2 mM dNTPs, 0.5 mM nested
constant region and nested variable region primers]. First round
PCR was cycled as follows: 95uC65 min, 35 cycles of [95uC630 s,
55uC( V H and Vk)o r5 0 uC( V l)660 s, 72uC690 s] and one cycle
72uC67 min. Second round PCR was similar except the extension
step was performed at 58uC( V H), 60uC( V k), or 64uC( V l).
Products were analyzed using agarose gels (1.2%) and purified
using PCR purification kits (QIAGEN, Valencia, CA).
Products were sequenced in forward and reverse directions
using a BigDyeH sequencing kit on an ABI 3700 (Applied
Biosystems, Foster City, CA). Sequence base calling was
performed using Phred [50,51]; forward and reverse strands were
assembled using an assembly algorithm based on the quality scores
at each position [52]. The estimated PCR artifact rate was 0.28 or
approximately one PCR artifact per five genes amplified. Ig
isotype was determined by local alignment with genes of known
isotype [53]; V, D, and J region genes, CDR3 loop lengths, and
mutation frequencies were identified using SoDA [54]. All data
was annotated so that matching subject data and sort information
was linked to the cDNA sequence and analysis results.
For this analysis, when two LC were paired with a single HC (55
from TIV, 60 from EI) the LC with the higher estimated frequency
of mutation as calculated by SoDA was selected for inclusion in the
dataset. This resulted in unambiguous selection in 114 cases. In
one case both LC had an estimated rate of mutation of 0%; in this
case the LC was selected at random. Both possible members of this
pair were tested for binding and neither pairing was found to be
reactive with any antigen tested.
Clonal lineage determination
Antibody gene sequences from individual subjects were grouped
and analyzed using the following criteria: 1) matching of variable
and joining region gene segments; 2) matching of CDR3 loop
lengths; and 3) $70% homology in CDR3 nucleotide sequence.
Clonal lineages were only identified if both heavy and light chains
for a given group satisfied all three criteria. For heavy chain
alignments, D region usage was not considered; i.e., heavy chain
genes could be considered part of a clonal lineage if they satisfied
the above three criteria but had different predicted D region gene
usage. Maximum likelihood trees for clonal lineages were
generated using V(D)J regions (excluding constant region sequenc-
es); trees were constructed (dnaml), reorganized (retree), and
plotted (drawgram) with the PHYLIP 3.69 package [55]. Inferred
intermediate VH and VL sequences generated by dnaml were
synthesized (GeneScript, Piscataway, NJ) and expressed as IgG1
rmAbs as described below.
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mAbs
Isolated Ig VH and VL gene pairs were assembled by PCR into
linear full-length Ig heavy- and light-chain gene expression
cassettes using methods as described [14]. Human embryonic
kidney cell line 293T (ATCC, Manassas, VA) was grown to near
confluence in 6-well tissue culture plates (Becton Dickinson,
Franklin Lakes, NJ) and transfected with 2 mg per well of both IgH
and IgL purified PCR-produced cassettes using PolyFect or
Effectene (QIAGEN, Valencia, CA). For PolyFect transfected
cells, six to eight hours after transfection cells were fed with fresh
culture medium supplemented with 2% fetal bovine serum and
were incubated at 37uC in a 5% CO2 incubator. For Effectene
transfected cells, this wash step was omitted. Culture supernatants
were harvested three days after transfection and concentrated
four-fold using centrifugal concentrators; expressed IgG was
quantitated by ELISA [56]; tested mAbs were expressed at
10 mg/mL up to 20 mg/mL. For larger scale production of
recombinant mAbs, some linear IgH and IgL gene constructs were
cloned into pcDNA 3.3 using standard molecular protocols.
Antibody binding by ELISA, LuminexH and indirect
immunofluorescence
Plasma samples from both subject cohorts were evaluated by
ELISA [57] against a panel of baculovirus-expressed purified
hemagglutinins (H1 A/Solomon Islands/03/2006, H1 A/Bris-
bane/59/2007, H1 A/California/04/2009, H3 A/Wisconsin/
67/2005, H3 A/Brisbane/10/2007, H3 A/Johannesburg/33/
1994, H5 A/Vietnam/1203/2004, H5 A/Indonesia/05/2005, B/
Florida/04/2006) (Protein Sciences, Meridien, CT) and split virus
vaccine preparations [2007–2008 FluzoneH vaccine containing A/
Solomon Islands/3/2006 (H1N1), A/Wisconsin/67/2005
(H3N2), and B/Malaysia/2506/2004; 2008–2009 FluzoneH
vaccine containing A/Brisbane/59/2007 (H1N1), A/Uruguay/
716/2007 (H3N2) (classified as a A/Brisbane/10/2007-like
strain), and B/Florida/04/2006] (Sanofi Pasteur, Swiftwater
PA). Split-virus vaccine products have been previously shown to
contain HA, neuraminidase, nucleoprotein, matrix protein, and
membrane fragments [15]. Samples were diluted serially for the
analysis and data were analyzed using 5-parameter curve fitting;
endpoint titers were calculated as 3-fold above assay background.
The assay cutoff was a 1:25 dilution. Expressed mAbs were tested
in the same ELISA system. ELISA testing for antigens was
considered positive if the optical density reading was above 0.13
units, except in the case of split virus influenza vaccine ELISA
which was considered positive if the optical density reading was
above 0.20 units. Affinity of rmAbs was determined using 4-
parameter curve fit of ELISA titer data.
Reactivity to influenza antigens was also studied using a
standardized custom LuminexH assay [58]. LuminexH assays were
considered positive if the blank-bead-subtracted value was greater
than 20 units and greater than 10 divided by IgG concentration in
mg/mL.
Transiently expressed mAbs with low IgG concentration were
re-transfected and re-assayed. In cases where multiple tests of the
same antibody were available, the final dataset contained data
from the assay with the highest concentration of mAb. In order to
account for antigen overlap between influenza vaccines and
purified HAs, antigen reactivities were condensed if reactivity was
found to certain antigen pairs (e.g., mAb reactivity to both
influenza vaccine 2007–2008 and H3 A/Wisconsin/67/2005 was
counted singly). Antigen pairs treated this way were as follows:
2007–2008 vaccine & H1 A/Solomon Islands/03/2006; 2007–
2008 vaccine & H3 A/Wisconsin/67/2005; 2008–2009 vaccine &
H1 A/Brisbane/59/2007; 2008–2009 vaccine & H3 A/Brisbane/
10/2007; 2008–2009 vaccine & B/Florida/04/2006.
Surface Plasmon resonance (SPR) analysis of antibody
reactivity
SPR binding assays were performed on a BIAcore 3000
(BIAcore Inc, Piscataway, NJ) maintained at 20uC. HA recombi-
nant protein was immobilized on a CM5 sensor chip by standard
amine coupling as described [57,59]. Additional tests were
performed by capturing human mAbs on anti-human Fc
antibody-coupled surfaces; each human mAb was captured to
about 200–500 RU. Specific binding responses of mAb binding
were obtained following subtraction of non-specific binding on
control surfaces. Rate constants were measured using the bivalent
analyte model (to account for the avidity of bivalent Ig molecules)
and global curve fitting to binding curves obtained from mAb
titrations. Antibodies were injected at 30 mL/min for 2–6 min;
glycine-HCl pH 2.0 was used as the regeneration buffer.
Hemagglutination Inhibition (HAI) Assay and Influenza
Microneutralization Assay
The hemagglutination inhibition (HAI) assay and microneu-
tralization assays were based on standard published protocols [60].
Influenza stocks were grown in embryonated eggs and were titered
for hemagglutination units on turkey red blood cells. To perform
HAI assays, serial dilutions in PBS of plasma or transfected cell
supernatants were placed into 96-well plates and were mixed with
an equal volume of washed turkey red blood cells (0.5%) and
incubated at room temperature for 30 min before hemagglutina-
tion was read directly from the wells.
For microneutralization, MDCK cells were cultured as mono-
layers in 96-well culture plates at 37uCi n5 %C O 2, followed by the
addition of mixtures of serial dilutions of plasma or purified mAbs
and 100 TCID50 of the appropriate infectious influenza virus stock.
Plates were incubated at 37uCi n5 %C O 2 for 18 h prior to assay.
Final assay of the infectious cultures was performed by using
fluorescence (for virus constructs containing fluorescent reporter
genes); by ELISA using mouse mAb anti-Influenza A nucleoprotein
(BEI resources, Manassas, VA) at 1:4000 dilution, followed by
HRP-conjugatedGoatanti-mouse IgG(KPL,Gaithersberg,MD)at
1:2,500 dilution (according to CDC SOP); or by testing of the
resulting virus cultures in HAI as described above.
Statistical analysis
Statistical tests were performed in SAS v9.2 (SAS Institute,
Cary, NC). Comparisons for multiple groups (i.e., CDR3 length,
mutation rate) were performed using multiple degree of freedom
F-tests using PROC GLM in SAS v9.2 with subsequent pairwise
comparisons. For data consisting of two groups only, t-tests using
the Satterthwaite correction (for continuous variables), the
Kolmogorov-Smirnov test (for comparison of probability distribu-
tions), and Pearson’s chi squared tests (for 262 category tables)
were performed using the appropriate SAS PROC in SAS v9.2;
the statistical test used is noted when p-values are presented.
Graphs of the data were created using GraphPad Prism
(GraphPad Software, La Jolla, CA) with layout in Illustrator
CS4 (Adobe, San Jose, CA).
Supporting Information
Text S1 Additional description of results presented in
Supplemental Information.
(PDF)
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from TIV and EI subjects. Plasma samples from day 0 and
from day 21 (TIV) or day 28 (EI) were tested by ELISA for binding
to split virus vaccine preparations and to purified recombinant
hemagglutinins. For subject EI03, no day 28 plasma sample was
available; a day 7 plasma sample was substituted for this analysis.
ELISA was performed using serial dilutions and optical density
readings were fitted to a 5-parameter curve; endpoint titers were
determined as three fold over the background of the assay for each
run. Data are plotted as reciprocal titer values and are pre-
immunization/pre-infection titer (x-axis) vs. post-immunization/
post-infection titer (y-axis). The threshold of the assay was 1:25
dilution; endpoint titers that fell below that cutoff were adjusted to
that value. The diagonal line for each plot represents a four-fold
rise in titer; distance above the diagonal line is proportional to
boosting. Each antigen is represented by a number or letter; these
are color coded (blue for antigens contained in the 2007–2008
vaccine, red for antigens in the 2008–2009 vaccine, black for
antigens unrelated to either vaccine). The code for the graphs is as
follows: 7=2007–2008 influenza vaccine (blue); S=H1 A/
Solomon Islands/03/2006 (blue); W=H3 A/Wisconsin/67/
2005 (blue); 8=2008–2009 influenza vaccine (red); Z=H1 A/
Brisbane/59/2007 (red); N=H3 A/Brisbane/10/2007 (red);
B=B/Florida/04/2006 (red); J=H3 A/Johannesburg/33/1994
(black); I=H5 A/Indonesia/05/2005 (black); V=H5 A/Viet-
nam/1203/2004 (black); H=H1 A/California/04/2009 (black).
For individual subjects, reactivity to specific strains was found to
dominate. TIV01: rise against S=H1 A/Solomon Islands/03/
2006. TIV04: rise against S=H1 A/Solomon Islands/03/2006.
TIV14: No clear dominant response. TIV21: rise against
8=2008–2009 influenza vaccine and B=B/Florida/04/2006.
TIV24: rise against 8=2008–2009 influenza vaccine and Z=H1
A/Brisbane/59/2007. Cross-reactive response to S=H1 A/
Solomon Islands/03/2006. EI02: slight rise against W=H3 A/
Wisconsin/67/2005 and N=H3 A/Brisbane/10/2007 (points
overlap). EI03: data derived from day 0 and day 7 samples, 3.73-
fold rise against W=H3 A/Wisconsin/67/2005. EI05: rise against
W=H3 A/Wisconsin/67/2005 and N=H3 A/Brisbane/10/
2007 (points overlap). EI07: modest rise against W=H3 A/
Wisconsin/67/2005, N=H3 A/Brisbane/10/2007, J=H3 A/
Johannesburg/33/1994, and H=H1 A/California/04/2009 (J
and H points overlap). EI12: rise against W=H3 A/Wisconsin/
67/2005 and N=H3 A/Brisbane/10/2007 (points overlap). EI13:
modest rise against W=H3 A/Wisconsin/67/2005 (13.7-fold) and
N=H3 A/Brisbane/10/2007 (14.7-fold) (points overlap).
(PDF)
Figure S2 Plasmacytosis following TIV or EI. Plots shown
are of total B cell populations (CD3/14/16/235a
2 CD19
+) and
are normalized to 10000 events per panel. Ellipse in upper right
corner of each panel is homologous to the sorting gate used for the
isolation of single plasma cells for mAb generation. Additional
gating on CD20 was also performed for cell sorting and the final
population sorted for mAb production was CD3/14/16/235a
2
CD19
+ CD20
2/lo CD27
hi CD38
hi. Percentages shown are of
plasma cells as a fraction of total B cells.
(PDF)
Figure S3 Reactivities of human rmAbs recovered from
TIV and EI. A. Antibodies from TIV subjects. We recovered
plasma cells producing rmAbs against influenza antigens from all
TIV subjects. In two subjects (TIV01 and TIV21) the majority of
recovered rmAbs were reactive with influenza [179/245 (73%)
and 39/41 (95%), respectively]. In the other three subjects, less
than half of recovered rmAbs were influenza-specific [TIV04 8/17
(47%), TIV14 1/16 (6%), TIV24 35/85 (41%)]. B. Antibodies
from EI subjects. We recovered plasma cells producing rmAbs
against influenza antigens from five of six EI subjects; from one
subject (EI12) we recovered 51 rmAbs that were not reactive for
any antigen tested. None of the other EI subjects had more than
25% of rmAbs reactive with influenza [EI02 4/31 (13%), EI03
11/108 (10%), EI05 3/141 (2.1%), EI07 3/34 (9%), EI13 18/86
(21%)].
(PDF)
Figure S4 Relationship between influenza reactivity and
clonal lineages from TIV and EI subjects. Influenza-specific
rmAbs recovered from TIV were more likely to be in a clonal
lineage compared with EI. In TIV, 93/404 (23%) of rmAbs were
influenza-specific but not a member of a clonal lineage (blue
wedge), 159/404 (39%) were both influenza-specific and members
of clonal lineages (purple wedge), while only 16/404 (4%) were
members of clonal lineages but not reactive with influenza
antigens (red wedge). In EI, 31/451 (6.9%) were influenza-specific
but not part of a clonal lineage, 6/451 (1.3%) were both influenza-
specific and part of a clonal lineage, and 22/451 (4.9%) were not
influenza specific but were part of a clonal lineage.
(PDF)
Figure S5 VDJ mutation rate of influenza-specific mAbs
from TIV and EI subjects. VDJ mutation rates in rmAbs from
TIV subjects (range 0.9–30.3%, mean 5.8%60.2%) were lower on
average than rmAbs from EI subjects (range 0.4–15.8%, mean
8.6%60.6%) (two-tailed t-test, p,0.0001).
(PDF)
Figure S6 VDJ mutation rate of influenza-specific mAbs
from TIV and EI subjects by isotype of mAb. A. HC
isotype of influenza-specific rmAbs from TIV subjects were found
to be predominantly IgG1 (201/252, 80%), followed by IgA1 (36/
252, 14%) and IgM (9/252, 3.6%). VDJ mutation rates for these
three isotypes were as follows: IgG1 5.9%60.2%, IgA1
6.1%60.8%, IgM 3.9%60.4%. Comparison of mutation rates
between isotypes within the TIV group did not show any
significant differences. B. HC isotype of influenza-specific rmAbs
from EI subjects were also found to be predominantly IgG1 (23/
37, 62%), followed by IgA1 (7/37, 19%) and IgM (5/37, 14%).
VDJ mutation rates for these three isotypes were as follows: IgG1
9.1%60.7%, IgA1 7.2%61.7%, IgM 8.2%62.1%. Comparison
of mutation rates between isotypes within the EI group did not
show any significant differences. When compared between the
TIV and EI groups, however, mutation rates for both IgG1 and
IgM were found to be higher in rmAbs derived from EI subjects
vs. those derived from TIV subjects (two-tailed t-test, p,0.0001 for
IgG1, p=0.033 for IgM).
(PDF)
Figure S7 HC CDR3 length distribution of mAbs from
TIV and EI subjects. A. HC CDR3 length distribution of all
mAbs isolated from TIV subjects showed a predominance of
mAbs with length 19; as with influenza-specific mAbs (Fig. S7C
online) a large portion of this was contributed by 13 clonal lineages
from one subject (TIV01) that had similar heavy chain
rearrangements (VH4-59–JH6) but that did not share light chains.
These clonal lineages contributed 68 mAbs (gray portion of bar).
B. HC CDR3 length distribution of all mAbs isolated from EI
subjects showed a distribution similar to that of the influenza-
specific rmAbs (Fig. S7D online). As with influenza-specific mAbs,
HC CDR3 lengths of 16 were the most common overall.
Kolmogorov-Smirnov test of the distributions in A and B showed
a difference in distribution (test statistic=4.67, p,0.0001). C. HC
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PLoS ONE | www.plosone.org 11 October 2011 | Volume 6 | Issue 10 | e25797CDR3 length distribution of influenza-specific rmAbs from TIV
subjects. The number of aas in HC CDR3 was most commonly
19; 13 clonal lineages from subject TIV01 with similar
rearrangements (VH4-59–JH6) contributed 65 rmAbs to this peak
(gray portion of bar). D. HC CDR3 length distribution of
influenza-specific rmAbs from EI subjects. HC CDR3 lengths of
16 were most common. Kolmogorov-Smirnov test of the
distributions in C and D showed a difference in distribution (test
statistic=2.25, p,0.0001).
(PDF)
Figure S8 Distribution of rmAb reactivities among
influenza-specific rmAbs from TIV and EI subjects. For
each tested antigen, influenza-specific rmAbs were counted to
determine how many rmAbs reacted with that antigen. In contrast
to the other analyses, each reactivity was counted separately (e.g.,
rmAb reactive with 2007–2008 influenza vaccine and with H3 A/
Wisconsin/67/2005 was counted as positive for both columns).
Multiply reactive rmAbs were counted as positive for each antigen
with which they reacted; bars do not sum to 100% for this analysis.
For each TIV subject, rmAb reactivity was found to be primarily
specific for individual strains. TIV01 (173 influenza-specific
rmAbs): 171/173 (98.9%) reacted with 2007–2008 influenza
vaccine, 149/173 (86%) reacted with H1 A/Solomon Islands/03/
2006 while only 1/173 (0.6%) reacted with H3 A/Wisconsin/67/
2005. SPR testing of rmAbs derived from subject TIV01 bound to
rHA H1 A/Solomon Islands/03/2006 but not to H3 A/
Wisconsin/67/2005 (Figs. S9A, S9B, S9C online). TIV04 (8
influenza-specific rmAbs): 8/8 (100%) reacted with 2007–2008
influenza vaccine, 2/8 (25%) reacted with H1 A/Solomon
Islands/03/2006; no other reactivities detected. TIV14 omitted
from this analysis as there was only one influenza-specific rmAb
isolated (this rmAb reacted with 2007–2008 influenza vaccine, H1
A/Solomon Islands/03/2006, and H1 A/Brisbane/59/2007).
TIV21 (39 influenza-specific rmAbs): 39/39 (100%) reacted with
2008–2009 influenza vaccine, 28/39 (72%) reacted with HA B/
Florida/04/2006, while only 5/39 (13%) reacted with H1 A/
Brisbane/59/2007 and 2/39 (5%) reacted with H3 A/Brisbane/
10/2007. TIV24 (31 influenza-specific rmAbs): 26/31 (84%)
reacted with 2008–2009 influenza vaccine, 18/31 (58%) reacted
with H1 A/Brisbane/59/2007, while only 2/31 (6%) reacted with
H3 A/Brisbane/10/2007 and 1/31 (3%) reacted with HA B/
Florida/04/2006. Additionally, 18/31 (58%) reacted with H1 A/
Solomon Islands/03/2006, however, only 4/31 (13%) reacted
with 2007–2008 influenza vaccine. For EI subjects, rmAbs were
more commonly cross-reactive/less dominantly directed against
single influenza strains. EI02 (4 influenza-specific rmAbs): 3/4
(75%) reacted with 2007–2008 influenza vaccine, 2/4 (50%)
reacted with H3 A/Wisconsin/67/2005, 2/4 (50%) reacted with
H3 A/Brisbane/10/2007, and 3/4 (75%) reacted with H3 A/
Johannesburg/33/1994. No rmAbs reacted with H1, H5, or B
strain HAs. EI03 (10 influenza-specific rmAbs): 4/10 (40%)
reacted with 2007–2008 influenza vaccine, 3/10 (30%) rmAbs
reacted with 2008–2009 influenza vaccine, 4/10 (40%) reacted
with H3 A/Wisconsin/67/2005, 5/10 (50%) reacted with H3 A/
Brisbane/10/2007, and 8/10 (80%) reacted with H3 A/
Johannesburg/33/1994. Additionally, 1/10 (10%) reacted with
H1 A/California/04/2009; no binding was found to other H1,
H5, or B strain HAs. EI05 (3 influenza-specific rmAbs): 1/3 (33%)
reacted with 2007–2008 influenza vaccine, 2/3 (67%) reacted with
H3 A/Wisconsin/67/2005 No binding was found to other H1,
H3, H5, or B strain HAs. EI07 (3 influenza-specific rmAbs): 1/3
(33%) reacted with 2007–2008 influenza vaccine, 1/3 (33%)
rmAbs reacted with 2008–2009 influenza vaccine, 2/3 (67%)
reacted with H3 A/Wisconsin/67/2005, 1/3 (33%) reacted with
H3 A/Brisbane/10/2007, and 2/3 (67%) reacted with H3 A/
Johannesburg/33/1994. No binding was found to other H1, H5,
or B strain HAs. EI12 was omitted as there were no influenza-
specific rmAbs isolated. EI13 (17 influenza-specific rmAbs): 8/17
(47%) reacted with 2007–2008 influenza vaccine, 8/17 (47%)
rmAbs reacted with 2008–2009 influenza vaccine, 7/17 (41%)
reacted with H3 A/Wisconsin/67/2005, 9/17 (53%) reacted with
H3 A/Brisbane/10/2007, and 9/17 (53%) reacted with H3 A/
Johannesburg/33/1994. Additionally, 1/17 (6%) reacted with H1
A/Solomon Islands/03/2006, 2/17 (12%) reacted with H1 A/
Brisbane/59/2007, 1/17 (6%) reacted with H1 A/California/04/
2009, and 4/17 (24%) reacted with B/Florida/04/2006. No
rmAbs reacted with H5 HAs. SPR testing of selected rmAbs from
EI13 showed binding to rHAs from both H1 A/Solomon Islands/
03/2006 and H3 A/Wisconsin/67/2005 (Figs. S9B, S9C online).
(PDF)
Figure S9 Surface plasmon resonance analysis of
rmAbs recovered from TIV and EI subjects. A. Human
rmAbs 1248, 1258, and 1270 from subject TIV01 bound to H1 A/
Solomon Islands/03/2006 bound to an SPR chip. B. Human rmAbs
1210 and 1267 from subject TIV01 and rmAbs 2210 and 2217 from
subject EI13 bound to H1 A/Solomon Islands/03/2006 bound to an
SPR chip. C. Human rmAbs 1267 and 1210 from subject TIV01 did
not bind to H3 A/Wisconsin/67/2005 bound to an SPR chip while
rmAbs 2210 and 2217 from subject EI13 did bind. D. Human rmAbs
from subjects TIV01 (1210 and 1267) and EI13 (2210 and 2217)
showed essentially no interaction with phosphatidylcholine-cardio-
lipin liposomes. Anti-HIV-1 mAb 4E10 is shown as a positive control
and anti-HIV-1 mAbs 2F5 and 13H11 are shown as negative
controls. E. Human rmAb 1258 from subject TIV01 shows some
degree of binding to phosphatidylcholine-cardiolipin liposomes while
rmAb 1270 from subject TIV01 shows a lesser degree of binding.
Anti-HIV-1 mAb 4E10 is shown as a positive control. No binding of
rmAbs to apoferritin (control protein) or to phosphatidylcholine-
phosphatidylserine liposomes was seen (data not shown).
(PDF)
Figure S10 Additional representative clonal lineage of
rmAbs from subject TIV01. Data for starred rmAbs appear in
Table S12 online. Clonal lineage 643 from subject TIV01. Sixteen of
17 rmAbs (94%) bound one antigen, 1/17 (6%) was not influenza-
specific. Four rmAbs were tested in additional assays.Affinity for rHA
binding was measured for three rmAbs and all had sub-nanomolar
affinity for rHA H1 A/Solomon Islands/03/2006 and no binding to
H3 A/Wisconsin/67/2005. Neutralization assays for one rmAb
(1267 IgG1) showed potent neutralization of H1N1 A/Solomon
Islands/03/2006, weak neutralization of H1N1 A/Brisbane/59/
2007 and no neutralization of H3N2 A/Wisconsin/67/2005. Two
other rmAbs were tested only against H1N1 A/Brisbane/59/2007
and neither neutralized. All four tested rmAbs showed potent HAI
against H1N1 A/Solomon Islands/03/2006; two rmAbs showed
weak HAI activity against H3N2 A/Wisconsin/67/2005.
(PDF)
Figure S11 Additional representative clonal lineages of
rmAbs from TIV subjects. A. Clonal lineage 690 from subject
TIV01. Three of 12 rmAbs (25%) bound one antigen, 8/12 (67%)
bound two antigens, 1/12 (8%) bound none. B. Clonal lineage
2737 from subject TIV21. Five of 8 rmAbs (63%) bound one
antigen, 3/8 (37%) bound two.
(PDF)
Figure S12 Sequence alignment of H3 HAs used in this
study. Amino acid sequences for H3 HA strains used in this study
were downloaded from PubMed and aligned to the H3 A/
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PLoS ONE | www.plosone.org 12 October 2011 | Volume 6 | Issue 10 | e25797Wisconsin/67/2005 sequence. Differences are highlighted in
colors for each aligned sequence. The H3 A/Johannesburg/33/
1994 strain was the least similar with 88.8% identity. Only the
HA1 sequence for the Johannesburg strain was available; all
sequences were aligned in this region only.
(PDF)
Table S1 Clonal lineages of antibodies from TIV
subjects.
(PDF)
Table S2 Clonal lineages of antibodies from EI sub-
jects.
(PDF)
Table S3 Isotypes of isolated influenza-specific rmAbs.
(PDF)
Table S4 Isotypes of isolated rmAbs not specific for
influenza antigens.
(PDF)
Table S5 Heavy chain family usage of influenza-specific
rmAbs.
(PDF)
Table S6 Heavy chain family usage of isolated rmAbs
not specific for influenza antigens.
(PDF)
Table S7 Kappa chain family usage of isolated influen-
za-specific rmAbs.
(PDF)
Table S8 Kappa chain family usage of isolated rmAbs
not specific for influenza antigens.
(PDF)
Table S9 Lambda chain family usage of isolated
influenza-specific rmAbs.
(PDF)
Table S10 Lambda chain family usage of isolated
rmAbs not specific for influenza antigens.
(PDF)
Table S11 Characteristics of cross-reactive rmAbs.
(PDF)
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